94 Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis

Clicks: 17
ID: 326732
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #205 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Metastatic non-small cell lung cancer (NSCLC) with synchronous brain metastases (BM) impacts prognosis and therapeutic considerations. Up to 20% patients with NSCLC may develop BM. Clinical trials of whole brain radiotherapy (WBRT), neurosurgical resection and stereotactic radiosurgery outdate the recent advances in systemic therapy for NSCLC. Methods Retrospective data was collected on all patients with NSCLC who presented with synchronous BM between 2017-2022. This included demographics, histological sub-type, programme death ligand-1 (PDL-1) status, genetic markers, types of intracranial treatments, primary cancer treatment, progression and survival. Results 200 patients were identified. Mean age was 65 years; median performance status was 1. Most common histological subtype was adenocarcinoma (82%); 14 patients had a targetable genetic mutation. PDL-1 status was >50%, 1-49%, and <1% in 78, 37, and 39 patients respectively. Median overall survival (OS) was 6.7 months. Median OS varied according to the type of NSCLC treatment patients received; it was 27, 15.4, 14.7, 7.6, and 2.9 months in patients treated with tyrosine kinase inhibitor (TKI), radical intent thoracic treatments, immunotherapy, chemotherapy, and best supportive care respectively. Median OS was 34, 14.7, 13.9, 6.2, and 4.8 months in patients who received multimodality treatment, neurosurgery, SRS, WBRT, and BSC respectively. There was so significant difference in number of patients receiving local brain treatment based on PDL1 and molecular genetic status. Conclusions The management of synchronous BM in patients with NSCLC poses a clinical conundrum. SRS, neurosurgical resection both offer survival advantage in patients receiving TKIs, immunotherapy, or radical treatment for the primary lung cancer whilst WBRT and chemotherapy have a limited impact. Prospective randomised clinical trials are needed to test the utility of upfront local intracranial treatments in this cohort.
Reference Key
openalex_W7204458128 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Harriet Hebbes, Sara Walters, Patrick Forster, Jillian Maclean, James Powell, Sahar Iqbal
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.032
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.032/70805867/noag172.032.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.